2020-02-26 09:17:12 09:17 02/26/20 02/2609:17 02/26/2009:17 | The Commodity Futures Trading Commission to hold a committee meetingThe Technology Advisory Committee will hear presentations on stablecoins, audit trails, compliance solutions, and cryptocurrency self-regulatory organizations, insurance, and custody. Additionally, the Committee will discuss and vote on a recommendation from its Cybersecurity Subcommittee regarding the Financial Services Sector Coordinating Council Cybersecurity Profile in a meeting being held at the CFTC Washington, D.C. offices on February 26 at 10 am. Webcast Link |
---|
Periodicals
|
Vector Acquisition near deal to take Rocket Lab USA public, WSJ reports »
20:46 02/28/21 02/2820:46 02/28/2120:46
VACQ
Vector Acquisition
Space-transportation… Space-transportation startup Rocket Lab USA is nearing an agreement to go public by merging with Vector Acquisition (VACQ), Cara Lombardo of Wall Street Journal reports, citing people familiar with the matter. The deal values Rocket Lab at around $4.1B including debt and could be finalized by Monday, sources told the Journal. It is expected to include additional funds of about $470M in the form of a private investment in public equity from investors including BlackRock (BLK) and Neuberger Berman Group, the sources added. Reference Link ShowHide Related Items >><<
|
Upgrade
|
Wolters Kluwer upgraded to Neutral from Sell at Goldman Sachs »
20:43 02/28/21 02/2820:43 02/28/2120:43
WTKWY
Wolters Kluwer
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Albireo Pharma price target raised to $81 from $68 at Piper Sandler »
20:41 02/28/21 02/2820:41 02/28/2120:41
ALBO
Albireo Pharma
Piper Sandler analyst… Piper Sandler analyst Yasmeen Rahimi raised the firm's price target on Albireo Pharma to $81 from $68 and keeps an Overweight rating on the shares. Following the earnings update, the analyst remains confident that Albireo is on track to launch odevixibat in the second half of 2021, with an FDA action date set for July 20. Her target raise is driven by odevixibat's "billion-dollar market opportunity" in biliary atresia. ShowHide Related Items >><<
|
Hot Stocks
|
Fly Intel: Top five weekend stock stories »
20:03 02/28/21 02/2820:03 02/28/2120:03
JNJ
Johnson & Johnson
Berkshire Hathaway
Berkshire Hathaway
Ross Stores
Twilio
Carlyle Group
American Electric
Dominion
Entergy
Exelon
NextEra Energy
Citi
Dow Inc.
Asos
Catch up on the… Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Food and Drug Administration issued an emergency use authorization for the third vaccine for the prevention of coronavirus disease. The EUA allows Johnson & Johnson's (JNJ) Janssen COVID-19 vaccine to be distributed in the U.S for use in individuals 18 years of age and older. Meanwhile, Johnson & Johnson also announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has recommended its single-shot COVID-19 vaccine. The ACIP recommendation will be forwarded to the Director of the CDC and the U.S. Department of Health and Human Services for review and adoption. Johnson & Johnson has begun shipping its COVID-19 vaccine and expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20M people in the U.S. The company plans to deliver 100M single-shot vaccines to the U.S. during the first half of 2021. The U.S. government will manage allocation and distribution of the vaccine in the U.S. 2. Warren Buffett Berkshire Hathaway's (BRK.A, BRK.B) fourth quarter profits rose, with its net earnings rising to $38.5B, or $23,015 a Class A share equivalent, up almost 23% from the previous year's profit of $29.2B, or $17,909 a share. Operating earnings, which exclude some investment results, rose to $5 billion from $4.4 billion the year before. Buffett also said in his annual shareholder letter to "never bet against America." "In its brief 232 years of existence... there has been no incubator for unleashing human potential like America," he added. "Despite some severe interruptions, our country's economic progress has been breathtaking. Our unwavering conclusion: Never bet against America." Buffett said the conglomerate owns the biggest amount of U.S. assets by value than any other company in the country. Berkshire Hathaway also bought back a record amount of company stock last year. During the fourth quarter, the company bought back about $9B shares for a total 2020 repurchase of $24.7B. Buffett said in his annual shareholder letter that repurchases have continued since year-end and "is likely to further reduce its share count in the future." 3. Ross Stores (ROST) offers shoppers a chance to find overlooked "treasures" among a heap of discards and its stock could offer investors the same opportunity, Teresa Rivas wrote in this week's edition of Barron's. The company has had a tough time during the pandemic and its stock has took a bigger beating, the author noted. But the underperformance means that Ross also has the most to gain as more vaccines are given and reopening accelerates, Rivas added. 4. Twilio (TWLO) is in talks to invest as much as $750M in Carlyle Group's (CG) Syniverse Technologies in a precursor to a public listing, Cara Lombardo and Dana Cimilluca of Wall Street Journal reported, citing people familiar with the matter. The investment will be announced Monday and could be followed in the coming months by a merger between Syniverse and a special-purpose acquisition company, sources told the Journal. Such a deal could value Syniverse around $2B to $3B including debt, they added. The Twilio deal involves a commercial arrangement that would send a significant amount of business to Syniverse, which provides roaming, messaging and other telecommunications services, the sources said. 5. American Electric Power (AEP), Dominion Energy (D), Entergy (ETR), Exelon (EXC), NextEra Energy (NEE), Citigroup (C), Dow (DOW) and Asos (ASOMY) saw positive mentions in this week's edition of Barron's. ShowHide Related Items >><<
|
Periodicals
|
AstraZeneca sells stake in Moderna for over $1B, The Times reports »
19:59 02/28/21 02/2819:59 02/28/2119:59
AZN
AstraZeneca
Moderna
AstraZeneca (AZN) has… AstraZeneca (AZN) has sold its stake in Moderna (MRNA) for more than $1B after the latter's shares soared on the back of its coronavirus vaccine breakthrough, The Times' Alex Ralph reports. AstraZeneca has disposed of its 7.7% holding, which had made it Moderna's second largest investor last year, the author notes. Reference Link ShowHide Related Items >><<
|
Earnings
|
Liberty Latin America reports Q4 revenue $1.10B, consensus $1.03B »
19:55 02/28/21 02/2819:55 02/28/2119:55
LILA
Liberty Latin America
Liberty Latin America
Reports Q4 adjusted FCF… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
On24 initiated with a Buy at Goldman Sachs »
19:28 02/28/21 02/2819:28 02/28/2119:28
ONTF
On24
Goldman Sachs analyst… Goldman Sachs analyst Christopher Merwin initiated coverage of On24 with a Buy rating and $88 price target. ON24 was a "significant beneficiary" as events shifted completely online in the past year as the company is able to capture rich data from webinar attendees that can be used to add context around a prospective customer's interest and intent to buy, Merwin tells investors in a research note. And if in-person events start to return in late 2021, On24 won't see major growth headwinds as most companies are likely to employ a hybrid strategy going forward and a majority of On24's deals are based on seat count, not webinar usage, says the analyst. Merwin models revenue growth of 30% and 22% in 2021 and 2022, respectively. ShowHide Related Items >><<
|
Periodicals
|
Herbalife to name three new directors as Icahn ends investment, WSJ reports »
19:24 02/28/21 02/2819:24 02/28/2119:24
HLF
Herbalife Nutrition
Herbalife Nutrition plans… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Twilio nears up to $750M investment in Syniverse, WSJ reports »
19:20 02/28/21 02/2819:20 02/28/2119:20
TWLO
Twilio
Carlyle Group
Twilio (TWLO) is in talks… Twilio (TWLO) is in talks to invest as much as $750M in Carlyle Group's (CG) Syniverse Technologies in a precursor to a public listing, Cara Lombardo and Dana Cimilluca of Wall Street Journal report, citing people familiar with the matter. The investment will be announced Monday and could be followed in the coming months by a merger between Syniverse and a special-purpose acquisition company, sources told the Journal. Such a deal could value Syniverse around $2B to $3B including debt, they added. The Twilio deal involves a commercial arrangement that would send a significant amount of business to Syniverse, which provides roaming, messaging and other telecommunications services, the sources said. Reference Link ShowHide Related Items >><<
|
Periodicals
|
CAE near deal to acquire L3Harris military-training unit, WSJ reports »
19:16 02/28/21 02/2819:16 02/28/2119:16
CAE
CAE
L3Harris Technologies
CAE (CAE) is nearing a… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Macy's, Gap letting customers buy now, pay later, WSJ reports »
18:12 02/28/21 02/2818:12 02/28/2118:12
M
Macy's
Gap
Affirm
Chains from Macy's… Chains from Macy's (M) to Gap (GPS) to Neiman Marcus Group have introduced buy now, pay later options in recent months to attract younger shoppers, who are less likely to use credit cards, The Wall Street Journal's Suzanne Kapner reports. The emerging payment option is a modern take on old-fashioned layaway plans, allowing shoppers to pay for purchases over time, the author notes. Instead of earning a profit from customers who revolve a balance on their store cards, retailers pay fees to the financial-technology companies that offer buy now, pay later plans, including Klarna Bank AB, Affirm Holdings (AFRM) and Afterpay, the publication adds. Reference Link ShowHide Related Items >><<
|
Periodicals
|
House approves Biden's $1.9T COVID aid, Reuters reports »
18:08 02/28/21 02/2818:08 02/28/2118:08
SPY
SPDR S&P 500 ETF Trust
S&P 500
President Joe… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Reliance partners with Google, Facebook for payment network bid, Reuters says »
18:07 02/28/21 02/2818:07 02/28/2118:07
FB
Alphabet
Alphabet Class A
India's conglomerate… India's conglomerate Reliance Industries has partnered with Facebook (FB), Google (GOOGL) and fintech player Infibeam to set up a national digital payment network, according to Reuters, citing a report by the Economic Times. Last year, India's central bank invited companies to forge new umbrella entities to create a payments network that would rival the system operated by the National Payments Council of India, as it seeks to reduce concentration risks in the space, the report notes. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Danone takes step to sell Chinese step amid shareholder pressure, Reuters says »
17:59 02/28/21 02/2817:59 02/28/2117:59
DANOY
Danone
Danone said on Sunday it… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Hyatt calls hate symbols 'abhorrent' after CPAC controversy, Reuters says »
17:56 02/28/21 02/2817:56 02/28/2117:56
H
Hyatt
Hyatt Hotels called… Hyatt Hotels called symbols of hate "abhorrent" on Sunday after the design of a stage at the Conservative Political Action Conference at one of its hotels drew comparisons to a Norse rune used by Nazis during World War Two, according to Reuters. High-profile Republicans including former President Donald Trump are attending the four-day event in Orlando, Florida, the publication notes. A photo of the CPAC stage went viral on social media on Saturday, with thousands of Twitter users sharing posts comparing its distinctive design to an othala rune, one of many ancient European symbols that Nazis adopted to "reconstruct a mythic 'Aryan' past," according to the Anti-Defamation League. Reference Link ShowHide Related Items >><<
|
Periodicals
|
McDonald's considering selling part of Dynamic Yield, Bloomberg reports »
17:47 02/28/21 02/2817:47 02/28/2117:47
MCD
McDonald's
McDonald's said it… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Microsoft says vaccine tools have 'fallen short,' Bloomberg reports »
17:43 02/28/21 02/2817:43 02/28/2117:43
MSFT
Microsoft
Widely-used Microsoft… Widely-used Microsoft vaccine scheduling software that has run into difficulties in states like Iowa and New Jersey is being blamed for problems that left some residents of the nation's capital unable to book appointments, Bloomberg's Ari Natter and Dina Bass report. After three straight days of issues with the District of Columbia's online vaccination registration, the company released a statement along with the city government acknowledging "that our efforts have fallen short" and vowing to address the problems, the authors note. "We understand the frustration of individuals who attempted to utilize the District's vaccination appointment portal this week," they said. "We are committed to address technical issues so that the vaccination appointment portal is properly functional and accessible." Reference Link ShowHide Related Items >><<
|
Hot Stocks
|
CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ »
17:41 02/28/21 02/2817:41 02/28/2117:41
JNJ
Johnson & Johnson
Johnson & Johnson… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
BridgeBio, affiliate Origin Biosciences announce FDA approval of NULIBRY »
16:14 02/28/21 02/2816:14 02/28/2116:14
BBIO
BridgeBio
BridgeBio Pharma and… BridgeBio Pharma and affiliate Origin Biosciences announced the U.S. Food and Drug Administration has approved NULIBRY for Injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A. This is the first therapy of its kind. The novel therapy was developed based on BridgeBio's commitment to developing a treatment for MoCD Type A in collaboration with the experts and families in the MoCD Type A community. MoCD Type A is an ultra-rare and progressive condition, known to impact less than 150 patients globally with a median survival of four years. MoCD Type A presents shortly after birth, often with severe encephalopathy and intractable seizures. NULIBRY is a first-in-class approved cPMP substrate replacement therapy. The efficacy of NULIBRY for the treatment of patients with MoCD Type A was established based on data from three clinical trials compared to data from a natural history study. In these studies, NULIBRY or recombinant cPMP reduced the risk of death by 82% compared to the untreated, genotype-matched, historical control group in the natural history study. At three years on study, the probability of survival in NULIBRY or rcPMP-treated patients was 84% compared to 55% for untreated genotype-matched patients in the historical control group at three years. In addition to the survival analysis, treatment with NULIBRY led to a reduction of urine concentrations of S-sulfocysteine, a toxic substance that leads to neurological damage, in patients with MoCD Type A, and the reduction was sustained with long-term treatment over 48 months. Animal studies have identified that NULIBRY has phototoxic potential. NULIBRY was reviewed under Priority Review and received Orphan Drug Designation, Breakthrough Therapy Designation and Rare Pediatric Disease Designation from the FDA. With this approval, the FDA also issued a Rare Pediatric Disease Priority Review Voucher to Origin. ShowHide Related Items >><<
|
Hot Stocks
|
Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 »
16:09 02/28/21 02/2816:09 02/28/2116:09
REGN
Regeneron
Regeneron Pharmaceuticals… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Harvey Norman downgraded to Neutral from Buy at Goldman Sachs »
10:49 02/28/21 02/2810:49 02/28/2110:49
HNORY
Harvey Norman
Goldman Sachs analyst… Goldman Sachs analyst Andrew McLennan downgraded Harvey Norman to Neutral from Buy with a price target of A$5.10. The analyst acknowledges that Harvey Norman delivered a "very strong" result in the first half of 2021. While conditions were still patchy and unpredictable in parts due to the pandemic, the company benefited substantially from the shift in spending by consumers on products and activities around the home over the first half of 2021 and it managed the business well under volatile, but strong trading conditions, McLennan contends. However, the analyst believes peak trading is unlikely to be sustained. ShowHide Related Items >><<
|
On The Fly
|
Opening Day: Coinbase files to go public »
10:13 02/28/21 02/2810:13 02/28/2110:13
FB
Score Media
Arya Sciences Acquisition Corp IV
Twelve Seas Investment Company II
Austerlitz Acquisition Corporation I
Austerlitz Acquisition Corporation II
Freedom Acquisition I
SilverBox Engaged Merger Corp I
Ibere Pharmaceuticals
Fusion Acquisition Corp. II
African Gold Acquisition
EJF Acquisition
Cartesian Growth
Soaring Eagle Acquisition
FTAC Athena Acquisition
Slam Corp.
Gores Holdings VII
Arctos NorthStar Acquisition
Coinbase
Roblox
Coupang
Caliber Home Loans
Pharming
Cricut
Gold Royalty
Oscar Health
Palantir
Asana
Slack Technologies
Spotify
Alibaba
Coinbase, the biggest… ShowHide Related Items >><<
|
Upgrade
|
Kalbe Farma upgraded to Buy from Neutral at Goldman Sachs »
09:43 02/28/21 02/2809:43 02/28/2109:43
PTKFF
Kalbe Farma
Goldman Sachs analyst… Goldman Sachs analyst June Zhu upgraded Kalbe Farma to Buy from Neutral. The analyst expects earnings growth for Kalbe Farma, Indonesia's biggest pharmaceutical and consumer health manufacturer, to break out from the "anemic levels" seen over the past five years. This new growth phase will be driven by less margin pressure for its prescription pharmaceutical business, oncology/biosimilar drugs' local manufacturing scaling up, rising health awareness, and higher distribution sales growth due to COVID treatment drugs and potentially vaccination given its cold-chain storage and extensive coverage, Zhu adds. ShowHide Related Items >><<
|
Conference/Events
|
FDA PDUFA Date for Athenex Oraxol (oral paclitaxel) is February 28, 2021
04:55 02/28/21 02/2804:55 02/28/2104:55
ATNX
Athenex
ShowHide Related Items >><<
|
Conference/Events
|
FDA PDUFA Date for CorMedix for Defencath is February 28, 2021
04:55 02/28/21 02/2804:55 02/28/2104:55
CRMD
CorMedix
ShowHide Related Items >><<
|